ReviewNutrients2026
Ketoanalogues of Essential Amino Acids in Chronic Kidney Disease: From Biochemical Rationale to Conditions for Clinical Effectiveness.
Review in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein restriction is an established nutritional intervention for selected adults with non-dialysis chronic kidney disease (CKD); a supplemented very-low-protein diet (sVLPD) combines marked protein restriction with essential amino acids and their nitrogen-free keto- and hydroxyanalogues (KAs). KAs may accept amino groups and regenerate essential amino acids while limiting exogenous nitrogen, but reversible transamination competes with irreversible oxidative decarboxylation. This narrative review integrates the biochemical pharmacology of KA/EAA mixtures with the clinical conditions required for effectiveness. Controlled and pragmatic trials are contrasted to distinguish efficacy under selected, adherent conditions from effectiveness in routine care. Safe implementation requires achieved protein restriction, adequate non-protein energy intake, correction of persistent metabolic acidosis, metabolic stability, administration with meals, appropriate dosing and structured monitoring; however, the specific effects of these conditions on in vivo KA disposition have not been quantified in advanced CKD. KA/EAA-supplemented VLPD may delay kidney replacement therapy in appropriately selected and supervised patients, but the supplement should be prescribed as part of a complete nutritional strategy rather than as an autonomous drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.